Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Krill oil extract suppresses the proliferation of colorectal cancer cells through activation of caspase 3/9.

Jayathilake AG, Kadife E, Luwor RB, Nurgali K, Su XQ.

Nutr Metab (Lond). 2019 Aug 17;16:53. doi: 10.1186/s12986-019-0382-3. eCollection 2019.

2.

Potent and Selective Cytotoxic and Anti-inflammatory Gold(III) Compounds Containing Cyclometalated Phosphine Sulfide Ligands.

Reddy TS, Pooja D, Privér SH, Luwor RB, Mirzadeh N, Ramesan S, Ramakrishna S, Karri S, Kuncha M, Bhargava SK.

Chemistry. 2019 Aug 14. doi: 10.1002/chem.201903388. [Epub ahead of print]

PMID:
31414501
3.

Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma.

Luwor R, Morokoff AP, Amiridis S, D'Abaco G, Paradiso L, Stylli SS, Nguyen HPT, Tarleton M, Young KA, O'Brien TJ, Robinson PJ, Chircop M, McCluskey A, Jones NC.

Cancer Invest. 2019;37(3):144-155. doi: 10.1080/07357907.2019.1582060. Epub 2019 Mar 25.

PMID:
30907150
4.

Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer.

Kadife E, Chan E, Luwor R, Kannourakis G, Findlay J, Ahmed N.

Cancers (Basel). 2019 Feb 19;11(2). pii: E243. doi: 10.3390/cancers11020243.

5.

Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies.

Tan FH, Putoczki TL, Stylli SS, Luwor RB.

Onco Targets Ther. 2019 Jan 18;12:635-645. doi: 10.2147/OTT.S189391. eCollection 2019. Review.

6.

Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth.

Tan FH, Putoczki TL, Lou J, Hinde E, Hollande F, Giraud J, Stylli SS, Paradiso L, Zhu HJ, Sieber OM, Luwor RB.

Cancers (Basel). 2018 Dec 19;10(12). pii: E526. doi: 10.3390/cancers10120526.

7.

Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance.

Atkins RJ, Stylli SS, Kurganovs N, Mangiola S, Nowell CJ, Ware TM, Corcoran NM, Brown DV, Kaye AH, Morokoff A, Luwor RB, Hovens CM, Mantamadiotis T.

Exp Cell Res. 2019 Jan 15;374(2):353-364. doi: 10.1016/j.yexcr.2018.12.010. Epub 2018 Dec 15.

PMID:
30562483
8.

The role of interleukin-6-STAT3 signalling in glioblastoma.

West AJ, Tsui V, Stylli SS, Nguyen HPT, Morokoff AP, Kaye AH, Luwor RB.

Oncol Lett. 2018 Oct;16(4):4095-4104. doi: 10.3892/ol.2018.9227. Epub 2018 Jul 27. Review.

9.

Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs.

Whitehead CA, Nguyen HPT, Morokoff AP, Luwor RB, Paradiso L, Kaye AH, Mantamadiotis T, Stylli SS.

Transl Oncol. 2018 Dec;11(6):1406-1418. doi: 10.1016/j.tranon.2018.08.012. Epub 2018 Sep 13.

10.

Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics.

Mitchell RA, Luwor RB, Burgess AW.

Exp Cell Res. 2018 Oct 1;371(1):1-19. doi: 10.1016/j.yexcr.2018.08.009. Epub 2018 Aug 9. Review.

PMID:
30098332
11.

Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer.

Zhai J, Luwor RB, Ahmed N, Escalona R, Tan FH, Fong C, Ratcliffe J, Scoble JA, Drummond CJ, Tran N.

ACS Appl Mater Interfaces. 2018 Aug 1;10(30):25174-25185. doi: 10.1021/acsami.8b08125. Epub 2018 Jul 20.

PMID:
29963859
12.

Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.

Chan E, Luwor R, Burns C, Kannourakis G, Findlay JK, Ahmed N.

Oncotarget. 2018 Mar 30;9(24):16599-16618. doi: 10.18632/oncotarget.24615. eCollection 2018 Mar 30.

13.

A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker.

Ma C, Nguyen HPT, Luwor RB, Stylli SS, Gogos A, Paradiso L, Kaye AH, Morokoff AP.

PLoS One. 2018 Feb 14;13(2):e0189452. doi: 10.1371/journal.pone.0189452. eCollection 2018.

14.

Effects of EphB4 receptor expression on colorectal cancer cells, tumor growth, vascularization and composition.

Kadife E, Ware TMB, Luwor RB, Chan STF, Nurgali K, Senior PV.

Acta Oncol. 2018 Aug;57(8):1043-1056. doi: 10.1080/0284186X.2018.1429650. Epub 2018 Jan 25.

PMID:
29368976
15.

Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide.

Mao L, Whitehead CA, Paradiso L, Kaye AH, Morokoff AP, Luwor RB, Stylli SS.

J Neurosurg. 2018 Sep;129(3):598-610. doi: 10.3171/2017.5.JNS17845. Epub 2017 Nov 17.

PMID:
29148898
16.

Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling.

Samardzija C, Greening DW, Escalona R, Chen M, Bilandzic M, Luwor R, Kannourakis G, Findlay JK, Ahmed N.

Sci Rep. 2017 Apr 13;7:46312. doi: 10.1038/srep46312.

17.

STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics.

Zulkifli AA, Tan FH, Putoczki TL, Stylli SS, Luwor RB.

Mol Cell Endocrinol. 2017 Aug 15;451:15-23. doi: 10.1016/j.mce.2017.01.010. Epub 2017 Jan 12. Review.

PMID:
28088467
18.

The emergent role of exosomes in glioma.

Gourlay J, Morokoff AP, Luwor RB, Zhu HJ, Kaye AH, Stylli SS.

J Clin Neurosci. 2017 Jan;35:13-23. doi: 10.1016/j.jocn.2016.09.021. Epub 2016 Oct 19. Review.

PMID:
27771233
19.

Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.

Samardzija C, Luwor RB, Quinn MA, Kannourakis G, Findlay JK, Ahmed N.

BMC Cancer. 2016 Jul 8;16:432. doi: 10.1186/s12885-016-2458-z.

20.

Defining the essential function of FBP/KSRP proteins: Drosophila Psi interacts with the mediator complex to modulate MYC transcription and tissue growth.

Guo L, Zaysteva O, Nie Z, Mitchell NC, Amanda Lee JE, Ware T, Parsons L, Luwor R, Poortinga G, Hannan RD, Levens DL, Quinn LM.

Nucleic Acids Res. 2016 Sep 19;44(16):7646-58. doi: 10.1093/nar/gkw461. Epub 2016 May 20.

21.

miRNA expression profiling of cerebrospinal fluid in patients with aneurysmal subarachnoid hemorrhage.

Stylli SS, Adamides AA, Koldej RM, Luwor RB, Ritchie DS, Ziogas J, Kaye AH.

J Neurosurg. 2017 Apr;126(4):1131-1139. doi: 10.3171/2016.1.JNS151454. Epub 2016 Apr 29.

PMID:
27128592
22.

Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.

Areeb Z, Stylli SS, Ware TM, Harris NC, Shukla L, Shayan R, Paradiso L, Li B, Morokoff AP, Kaye AH, Luwor RB.

Med Oncol. 2016 May;33(5):53. doi: 10.1007/s12032-016-0767-3. Epub 2016 Apr 20.

PMID:
27098175
23.

MicroRNA as potential biomarkers in Glioblastoma.

Areeb Z, Stylli SS, Koldej R, Ritchie DS, Siegal T, Morokoff AP, Kaye AH, Luwor RB.

J Neurooncol. 2015 Nov;125(2):237-48. doi: 10.1007/s11060-015-1912-0. Epub 2015 Sep 21. Review.

PMID:
26391593
24.

A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.

Samardzija C, Luwor RB, Volchek M, Quinn MA, Findlay JK, Ahmed N.

Mol Cancer. 2015 Aug 11;14:152. doi: 10.1186/s12943-015-0417-y.

25.

The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells.

Ching J, Amiridis S, Stylli SS, Bjorksten AR, Kountouri N, Zheng T, Paradiso L, Luwor RB, Morokoff AP, O'Brien TJ, Kaye AH.

Oncotarget. 2015 Aug 28;6(25):21301-14.

26.

SPSB1, a Novel Negative Regulator of the Transforming Growth Factor-β Signaling Pathway Targeting the Type II Receptor.

Liu S, Nheu T, Luwor R, Nicholson SE, Zhu HJ.

J Biol Chem. 2015 Jul 17;290(29):17894-908. doi: 10.1074/jbc.M114.607184. Epub 2015 Jun 1.

27.

Using bioluminescence imaging in glioma research.

Luwor RB, Stylli SS, Kaye AH.

J Clin Neurosci. 2015 May;22(5):779-84. doi: 10.1016/j.jocn.2014.11.001. Epub 2015 Mar 26. Review.

PMID:
25816780
28.

Single live cell TGF-β signalling imaging: breast cancer cell motility and migration is driven by sub-populations of cells with dynamic TGF-β-Smad3 activity.

Luwor RB, Hakmana D, Iaria J, Nheu TV, Simpson RJ, Zhu HJ.

Mol Cancer. 2015 Feb 22;14:50. doi: 10.1186/s12943-015-0309-1.

29.

Mouse models of glioma.

Stylli SS, Luwor RB, Ware TM, Tan F, Kaye AH.

J Clin Neurosci. 2015 Apr;22(4):619-26. doi: 10.1016/j.jocn.2014.10.013. Epub 2015 Feb 16. Review.

PMID:
25698543
30.

The role of STAT3 signaling in mediating tumor resistance to cancer therapy.

Tan FH, Putoczki TL, Stylli SS, Luwor RB.

Curr Drug Targets. 2014;15(14):1341-53. Review.

PMID:
25410411
31.

Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFκB-mediated induction of MMP2.

Bilandzic M, Wang Y, Ahmed N, Luwor RB, Zhu HJ, Findlay JK, Stenvers KL.

Cancer Lett. 2014 Nov 1;354(1):107-14. doi: 10.1016/j.canlet.2014.07.039. Epub 2014 Aug 13.

PMID:
25128652
32.

Expression of the adaptor protein Tks5 in human cancer: prognostic potential.

Stylli SS, Luwor RB, Kaye AH, I ST, Hovens CM, Lock P.

Oncol Rep. 2014 Sep;32(3):989-1002. doi: 10.3892/or.2014.3310. Epub 2014 Jul 4.

PMID:
24993883
33.

Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.

Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, Thompson EW, Findlay JK, Ahmed N.

BMC Cancer. 2014 May 6;14:317. doi: 10.1186/1471-2407-14-317.

34.

Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.

Abubaker K, Luwor RB, Escalona R, McNally O, Quinn MA, Thompson EW, Findlay JK, Ahmed N.

Front Oncol. 2014 Apr 9;4:75. doi: 10.3389/fonc.2014.00075. eCollection 2014.

35.

Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signalling.

Zhou F, Drabsch Y, Dekker TJ, de Vinuesa AG, Li Y, Hawinkels LJ, Sheppard KA, Goumans MJ, Luwor RB, de Vries CJ, Mesker WE, Tollenaar RA, Devilee P, Lu CX, Zhu H, Zhang L, Dijke PT.

Nat Commun. 2014 Mar 3;5:3388. doi: 10.1038/ncomms4388.

PMID:
24584437
36.

Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.

Ung N, Putoczki TL, Stylli SS, Ng I, Mariadason JM, Chan TA, Zhu HJ, Luwor RB.

Cancer Biol Ther. 2014 May;15(5):623-32. doi: 10.4161/cbt.28179. Epub 2014 Feb 20.

37.

Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.

Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, Nguyen PM, Preaudet A, Farid R, Edwards KM, Boglev Y, Luwor RB, Jarnicki A, Horst D, Boussioutas A, Heath JK, Sieber OM, Pleines I, Kile BT, Nash A, Greten FR, McKenzie BS, Ernst M.

Cancer Cell. 2013 Aug 12;24(2):257-71. doi: 10.1016/j.ccr.2013.06.017.

38.

Glycogen synthase kinase-3β (GSK-3β) and its dysregulation in glioblastoma multiforme.

Atkins RJ, Stylli SS, Luwor RB, Kaye AH, Hovens CM.

J Clin Neurosci. 2013 Sep;20(9):1185-92. doi: 10.1016/j.jocn.2013.02.003. Epub 2013 Jun 12. Review.

PMID:
23768967
39.

The role of Stat3 in glioblastoma multiforme.

Luwor RB, Stylli SS, Kaye AH.

J Clin Neurosci. 2013 Jul;20(7):907-11. doi: 10.1016/j.jocn.2013.03.006. Epub 2013 May 17. Review.

PMID:
23688441
40.

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.

Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, Thompson EW, Findlay JK, Ahmed N.

Mol Cancer. 2013 Mar 27;12:24. doi: 10.1186/1476-4598-12-24.

41.

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.

Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N.

PLoS One. 2012;7(10):e46858. doi: 10.1371/journal.pone.0046858. Epub 2012 Oct 8.

42.

Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo.

Luwor RB, Baradaran B, Taylor LE, Iaria J, Nheu TV, Amiry N, Hovens CM, Wang B, Kaye AH, Zhu HJ.

Oncogene. 2013 May 9;32(19):2433-41. doi: 10.1038/onc.2012.260. Epub 2012 Jul 2.

43.

Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation.

Luwor RB, Chin X, McGeachie AB, Robinson PJ, Zhu HJ.

Growth Factors. 2012 Aug;30(4):220-9. doi: 10.3109/08977194.2012.683189. Epub 2012 May 11.

PMID:
22574813
44.

New reagents for improved in vitro and in vivo examination of TGF-β signalling.

Luwor RB, Wang B, Nheu TV, Iaria J, Tsantikos E, Hibbs ML, Sieber OM, Zhu HJ.

Growth Factors. 2011 Oct;29(5):211-8. doi: 10.3109/08977194.2011.615311.

PMID:
21913800
45.

Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.

Luwor RB, Lu Y, Li X, Liang K, Fan Z.

Cancer Lett. 2011 Jul 1;306(1):85-91. doi: 10.1016/j.canlet.2011.02.035. Epub 2011 Mar 15.

46.

The EGFRvIII variant in glioblastoma multiforme.

Gan HK, Kaye AH, Luwor RB.

J Clin Neurosci. 2009 Jun;16(6):748-54. doi: 10.1016/j.jocn.2008.12.005. Epub 2009 Mar 25. Review.

PMID:
19324552
47.

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.

Garrett TP, Burgess AW, Gan HK, Luwor RB, Cartwright G, Walker F, Orchard SG, Clayton AH, Nice EC, Rothacker J, Catimel B, Cavenee WK, Old LJ, Stockert E, Ritter G, Adams TE, Hoyne PA, Wittrup D, Chao G, Cochran JR, Luo C, Lou M, Huyton T, Xu Y, Fairlie WD, Yao S, Scott AM, Johns TG.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5082-7. doi: 10.1073/pnas.0811559106. Epub 2009 Mar 16.

48.

Transforming growth factor-beta (TGF-beta) and brain tumours.

Luwor RB, Kaye AH, Zhu HJ.

J Clin Neurosci. 2008 Aug;15(8):845-55. doi: 10.1016/j.jocn.2008.01.003. Epub 2008 Jun 11. Review.

PMID:
18550374
49.
50.

Supplemental Content

Support Center